COUR’s CNP-101 for celiac disease, partnered with Takeda, is the first therapy to induce antigen-specific immune tolerance in any autoimmune disease in humans.
VALIDATED PLATFORM WITH BROAD APPLICATIONS
COUR’s Nanoparticle Platform (CNP) can be employed to induce disease-specific tolerance for the treatment of a myriad of autoimmune and allergic diseases by changing the antigen or allergen encapsulated within the nanoparticle.
With clinical validation from its lead therapeutic program, CNP-101 in celiac disease, COUR is advancing its pipeline of first-in-class therapies for immune-mediated disease.
We are a group of dedicated scientific, medical, and business professionals who are driven to find treatments and cures to immune-mediated diseases. By focusing our research at the root cause of disease, we seek to provide treatments previously unavailable to doctors and their patients.